Q-Med has received a first payment of $58.2 million from Medicis
Q-Med has received a first payment of $58.2 million from Medicis The American antitrust authority, Federal Trade Commission earlier approved Medicis (NYSE: MRX) acquisition of HA North American Sales AB from Q-Med. Q-Med has now received a first payment of $58.2 million from Medicis. The previously described deal generates a gross revenue and capital gain of $160 million, due as follows: approximately $58.2 million due upon closing of the transaction; approximately $53.3 million due upon Food and Drug Administration ("FDA") approval of RESTYLANE; approximately $19.4 million due upon certain